We have identified CL26 as a covalent inhibitor against AGPAT4, an aberrant protein complicated in hepatocellular carcinoma (HCC). CL26 treatment reversed HCC stemness and resistance to the first-line medication sorafenib. This experiment was conducted to investigate the protein targets of CL26 in MHCC97L cells.